ReviewCardiovascular research2023
Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.
Review in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Cardiac Modulation byCurrent issues in molecular biology · 2026Article
- Cardiotoxicity of Antitumor Agents: Therapeutic Challenges in Heart Failure with Reduced and Preserved Ejection Fraction.International journal of molecular sciences · 2026Review
- Bibliometric analysis of research trends and collaboration patterns in cardio-oncology focusing on lung cancer and heart failure.Discover oncology · 2026Article
- Multicenter machine learning prediction of postoperative heart failure in elderly patients highlighting inflammatory markers, metabolic comorbidities, and perioperative tachycardia.Frontiers in medicine · 2026Article
- Epigallocatechin Gallate as a Molecular Therapeutic in Heart Failure and Cardio-Oncology: Mechanistic Pathways and Translational Perspectives.International journal of molecular sciences · 2025Review
- Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides.European journal of heart failure · 2025Article
- Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.European journal of heart failure · 2025Article
- Genome-Wide Pleiotropy Analysis Identifies Shared and Opposing Pathways Influencing Coronary Artery Disease and Cancer.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure.American journal of preventive cardiology · 2025Article
- Angiotensin-Converting Enzyme Inhibitory Peptide Derived from UltrafineJournal of agricultural and food chemistry · 2025Article
- CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience.Cardio-oncology (London, England) · 2025Article
- Insights Into Heart-Tumor Interactions in Heart Failure.Circulation research · 2025Review
- Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50.Medicina (Kaunas, Lithuania) · 2025Article
- Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.Journal of cardiac failure · 2025Review
- Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.JACC. CardioOncology · 2025Review
- Attention-based deep learning for accurate cell image analysis.Scientific reports · 2025Article
- Identification and validation of biomarkers related to nicotinamide metabolic pathway activity in heart failure.Frontiers in genetics · 2025Article
- Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health.Cancers · 2024Article
- Cancer Prevention and Early Detection in Patients With Cardiovascular Disease: A Goal of Bidirectional Cardio-Oncology.JACC. CardioOncology · 2024Article
- Smoking Habits Following Cancer Diagnosis and Heart Failure.JAMA network open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Heart failure (HF) and cancer are the leading causes of death worldwide and accumulating evidence demonstrates that HF and cancer affect one another in a bidirectional way. Patients with HF are at increased risk for developing cancer, and HF is associated with accelerated tumour growth. The presence of malignancy may induce systemic metabolic, inflammatory, and microbial alterations resulting in impaired cardiac function. In addition to pathophysiologic mechanisms that are shared between cancer and HF, overlaps also exist between pathways required for normal cardiac physiology and for tumour growth. Therefore, these overlaps may also explain the increased risk for cardiotoxicity and HF as a result of targeted anti-cancer therapies. This review provides an overview of mechanisms involved in the bidirectional connection between HF and cancer, specifically focusing upon current 'hot-topics' in these shared mechanisms. It subsequently describes targeted anti-cancer therapies with cardiotoxic potential as a result of overlap between their anti-cancer targets and pathways required for normal cardiac function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.